# **Antiarrhythmic Drugs**



### Arrhythmia

Arrhythmia is an alteration in the normal sequence of electrical impulse rhythm that leads to contraction of the myocardium. It is manifested as an abnormality in the rate, in the site from which the impulses originate, or in the conduction through the myocardium. The rhythm of the heart normally is determined by a pacemaker site called the SA node, which consists of specialized cells that undergo spontaneous generation of action potentials at a rate of 100 to 110 action potentials ("beats") per minute. This intrinsic rhythm is strongly influenced by the vagus nerve, overcoming the sympathetic system at rest. This "vagal tone" brings the resting heart rate down to a normal sinus rhythm of 60 to 100 beats per minute. Sinus rates below this range are termed "sinus bradycardia," and sinus rates above this range are termed "sinus tachycardia." The sinus rhythm normally controls both atrial and ventricular rhythm. Action potentials generated by the SA node spread throughout the atria, depolarizing this tissue and causing atrial contraction. The impulse then travels into the ventricles via the AV node. Specialized conduction pathways within the ventricle rapidly conduct the wave of depolarization throughout the ventricles to elicit ventricular contraction. Therefore, normal cardiac rhythm is controlled by the pacemaker activity of the SA node. Abnormal or irregular cardiac rhythms (heartbeats) can occur when the SA node fails to function normally, when other pacemaker sites (e.g., ectopic pacemakers) trigger depolarization, or when a dysfunction occurs along the normal conduction pathways.



•If the arrhythmia arises from atria, SA node, or AV node it is called supraventricular arrhythmia

•If the arrhythmia arises from the ventricles it is called ventricular arrhythmia



Cardiac action potential recorded from a Purkinje fiber

## Arrhythmia

- Heart condition where disturbances in
  - Pacemaker impulse formation
  - Contraction impulse conduction
  - $^{\circ}$  Combination of the two



• Results in rate and/or timing of contraction of heart muscle that is insufficient to maintain normal cardiac output (CO)

Tachycardia (mostly seen)

Bradyarrhythmia for therapy Atropine (parasymphatolytic) β-mimetics: Efedrine Isoprenaline

- Metaproterenol
- Terbutaline

### **Antiarrhythmic Drugs**

- Causes of arrhythmia
- Arteriosclerosis
- Coronary artery spasm
- Heart block
- Myocardial ischemia

Drugs are classified by **Vaughan William** into four classes according to their effects on the cardiac action potential

Classification of antiarrhythmics (based on mechanisms of action)

Summary of the Cardiac Physiologic Effects of the Antiarrhythmic Drugs			
Classification	Mechanism of Action	Primary Sites of Action	Drug Examples
Class IA	Na* channel blockade		Quinidine
	Intermediate rate of dissociation from sodium channels		Procainamide
	Slows phase o depolarization	Atrial and ventricular tissue	Disopyramide
	Prolongs action potential duration		
	Slows conduction		
Class IB	Na* channel blockade		Lidocaine
	Rapid rate of dissociation from sodium channels		Mexiletine
	Shortens phase 3 repolarization	Ventricular tissue	Phenytoin
	Shortens action potential duration		Tocainide
Class 1C	Na* channel blockade	Ventricular tissue	Flecainide
	Slows rate of dissociation from sodium channels		Encainide
	Markedly slows phase o depolarization		Propafenone
	Slows conduction		Moricizine
Class II	Blocks sympathetic stimulation of $\beta_{_{\rm s}}\text{-adrenergic receptors}$	SA node	Propranolol
	Slows phase 4 depolarization	AV node	Sotalol
	Slows firing of SA node and conduction through AV node, prolonging repolarization		$\beta_{1}$ -Blockers
Class III	K* channel blockade (block delayed rectifier current)	Atrial and ventricular tissue	Amiodarone
	Prolongs phase 3 repolarization		Dronedarone Sotalol
	Prolongs duration of action potential, which prolongs refractory period		Bretylium
Class IV	Ca*2 channel blockade	SA node	Verapamil
	Slows phase 4 depolarization	AV node	Diltiazem
	Slows firing of SA node and conduction through AV node, prolonging repolarization of AV node		

### **Class IA Antiarrhythmic Drugs**

- Na Channel Blockade
- Cause moderate Phase 0 depression
- Prolong repolarization
- Increased duration of action potential.



\*2. Position aromatic hydroxylation \*O-Demethylation \*N-Oxidation \*3. Position allylic hydroxylation



**Quinidine** alkaloid from Cinchona officinalis L. bark

#### Procainamide (Pronestyl)



4-amino-N-(2-(diethylamino)ethyl)benzamide -Similarity to local anesthetic procaine (ester bio-isostere of procainamide)

- More resistant to both enzymatic and chemical hydrolysis

- Limited local anesthetic activity

#### Metabolism : via N-Acetyl transferase



### Disopyramide (Norpace, Rythmodul)



4-(diisopropylamino)-2-phenyl-2-(pyridin-2-yl)butanamide Cardiac effects are very similar to procainamide
 Used orally for treatment of ventricular and atrial arrhythmias

Metabolism: N-dealkylation (50% activity)

Adverse effects are primarily Anticholinergic ; dry mouth, blurred vision, constipation, and urinary retention



## **Class IB Antiarrhythmic Drugs :**

Used especially vetricular arrhythmias (VA)

(m-xylene is the common structure)

Compound	Formula
Lidocaine (Aritmal, Jetokain simpleks, Dolocain) 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide *Orally inactive-oxidative dealkylation	$\begin{array}{c} CH_{3} \\ H_{3} \\ H_{1} \\ CH_{3} \\ CH_{3} \end{array}$ Typically the drug of choice for emergency treatment of VA
<b>Tocainide (Xyloton)</b> 2-amino-N-(2,6-dimethylphenyl)propanamide	CH <sub>3</sub> H NH <sub>2</sub> OCH <sub>3</sub>
Mexiletine (Mexitil) 1-(2,6-dimethylphenoxy)propan-2-amine (can be used orally)	$H_3$ $H_2$ $CH_3$ $H_3$ $H_2$





### Metabolism



## Class IC Antiarrhythmic Drugs : mainly used in ventricular arrhythmia









### **CLASS II ANTIARRHYTHMIC DRUGS** : β-adrenergic receptor blockers



Methyl 3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanoate

Cardioselective  $\beta_1$ - receptor blocker with rapid onset, a very short duration of action (9 min.), and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages.

Decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

Incompatible with NaHCO<sub>3</sub>

Used for acut supraventricular tachycardia treatment

### Acebutolol is used to treat ventricular ve atrial arrhythmia



Cardioselective  $\beta_1$ - adrenergic receptor blocker.

Because of the intrinsic sympathomimetic activity acebutolol can be used safely for patient with <u>asthma</u> and <u>chronic obstructive pulmonary disease</u>

## **Class III Antiarrhythmic Drugs :**

#### Compound

### Formula

#### Amiodarone

(2-butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)-3,5diiodophenyl)methanone

#### **Bretylium tosylate**

(2-bromophenyl)methyl-ethyl-dimethylazanium; 4methylbenzenesulfonate adrenergic antagonist

\*\*Quaternary ammonium derivative, adrenergic neuron blocker. Antihypertansive.

#### **Sotalol**

N-(4-(1-hydroxy-2-(isopropylamino)ethyl)phenyl) methanesulfonamide

(Non selective beta blocker)

#### Sematilide

N-(2-(diethylamino)ethyl)-4-(methylsulfonamido) benzamide





**\*\***This drug is used to treat and suppress ventricular arrhythmias, particularly ventricular fibrillation and ventricular tachycardia especially *unresponsive to lidocaine and procainamide* 

Used to treat serious Ventricular fibrillation and Ventricular tachycardia (VT) .

$$CH_3SO_2NH \longrightarrow C_2H_5$$

Amiodarone:



- Amiodarone is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias.
- It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV.
- It has the potential for severe adverse effects including pulmonary toxicity, hepatic dysfunction, neuromuscular symptoms (e.g., peripheral neuropathy or proximal muscle weakness), photosensitivity, hypo- or hyperthyroidism (associated with the structural similarity to thyroid hormones), and QT prolongation.



### Metabolism

- The major metabolite, N-desethylamiodarone (DEA), is formed by N-deethylation. DEA also has antiarrhythmic properties. The elimination half-life of DEA is equal to or longer than that of the parent drug.
- A minor metabolite of amiodarone, di-N-desethylamiodarone
- Amiodarone and N-desethylamiodarone may undergo deiodination to form deiodoamiodarone and deiodo-N-desethylamiodarone, respectively.



Grapefruit juice can enhance the drug toxicity for antiarrhythmic agents, such as

- amiodarone,
- quinidine,
- disopyramide, or
- propafenone and
- for congestive heart failure drug carvedilol.

## **Class IV Antiarrhythmic Drugs :**

### Calcium Channel Blockers:

Causes a prolongation of the refractory period in the AV node and the atria and, thus, are very effective in treating supraventricular arrhythmias.

Verapamil and Diltiazem are prototype drug of this class, but dihydropyridine drugs are less effective in cardiac tissues.

Magnesium is natural CCB and used to treat VT/VF.